Outlook Therapeutics Inc
outlooktherapeutics.comWhat Do They Do?
Sells an eye-use bevacizumab treatment for wet age-related macular degeneration to clinics, hospitals and pharmacies.
10-K for FY2025, filed Dec 19, 2025
How Do They Make Money?
The company sells LYTENAVA to pharmaceutical wholesalers and distributors, and gets paid when the product is delivered; those customers then sell it to clinics, hospitals and pharmacies.
10-K for FY2025, filed Dec 19, 2025The Company recognizes revenue from sales of a single product, LYTENAVA (bevacizumab gamma) (the “Product”) in accordance with ASC Topic…View ↗
$1.4M
-
10-K for FY2025, filed Dec 19, 2025
$1.4M ↗
Who Are Their Customers?
The company sells to pharmaceutical wholesalers and distributors, which then resell LYTENAVA to clinics, hospitals and pharmacies.
10-K for FY2025, filed Dec 19, 2025The Company recognizes revenue from sales of a single product, LYTENAVA (bevacizumab gamma) (the “Product”) in accordance with ASC Topic…View ↗
Do Revenues Turn Into Profits?
No. It lost $62.4M in FY2025.
How Are They Changing?
- Net income
-
Sources
10-Q for Q3 FY2026, filed Aug 18, 2026
−$20.3MView ↗
- ▲ +1% (Loss)
- vs −$20.2M in Q3 FY2025
-
Aug 27, 2026
The company appointed a new CFO
Kevin Lundquist will take over from Lawrence Kenyon effective September 1, 2026.
Sources
8-K, filed Aug 27, 2026
On August 23, 2026, Outlook Therapeutics, Inc. (the “Company”) and Lawrence A. Kenyon, the Company’s Chief Financial Officer, Treasurer and…View ↗
-
Jul 24, 2026
The FDA approved LYTENAVA for wet AMD in the United States
Sources
8-K, filed Jul 24, 2026
On July 24, 2026, Outlook Therapeutics, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration…View ↗
From development to launch
The earlier report described the product as an investigational treatment still awaiting approvals; the latest says LYTENAVA is approved in Europe and the UK, with direct launches begun in Germany and the UK.
10-K for FY2022, filed Dec 29, 2022 10-K for FY2025, filed Dec 19, 2025We are a biopharmaceutical company that has developed ONS-5010/LYTENAVATM as the first ophthalmic formulation of bevacizumab approved by…View ↗
Who Do They Compete With?
Competes with Novartis, Regeneron, Genentech, Biogen, Coherus, Amgen, and Roche
10-K for FY2025, filed Dec 19, 2025We face competition from major multinational pharmaceutical companies, specialty pharmaceutical firms, and biotechnology companies. Key…View ↗
Loading...
